8-K: Personalis Reports Strong Q3 Revenue Growth, Raises Full-Year Guidance

Personalis, Inc. announced a 41% year-over-year revenue increase in Q3 2024, driven by a 96% surge in biopharma revenue, and raised its full-year revenue guidance.

Summary

• Personalis reported a 41% increase in total revenue for the third quarter of 2024, reaching $25.7 million, compared to $18.2 million in the same period last year.
• The company's biopharma revenue saw a significant 96% increase, rising to $15.7 million from $8.0 million year-over-year.
• Revenue from the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP) increased by 85% to $4.4 million.
• However, revenue from enterprise customers decreased by 33% to $5.3 million.
• Personalis delivered 945 molecular tests in Q3 2024, a 68% increase compared to the previous quarter.
• The company raised approximately $62.2 million in net financing proceeds from Tempus AI, Inc. through warrant exercises and stock purchases.
• An additional $27.2 million was raised through the company's At-The-Market (ATM) program.
• The company's cash balance stands at $143.7 million as of September 30, 2024, extending the expected runway into the first half of 2027.
• Personalis has revised its full-year 2024 revenue guidance to $83-$84 million, up from the previous $79-$81 million.
• The company expects a net loss of approximately $85 million for the full year, including $18 million in non-cash expenses related to warrants issued to Tempus.
• Cash usage for the full year is projected to be in the range of $53 to $55 million, down from the previous guidance of $60 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, successful capital raises, and increased full-year guidance. However, the net loss and decrease in enterprise revenue temper the overall optimism.

Positives

• The company experienced strong revenue growth, particularly in the biopharma sector.
• The increase in molecular tests delivered indicates growing demand for Personalis' services.
• The successful capital raises have significantly strengthened the company's financial position.
• The company has extended its cash runway into the first half of 2027.
• The company has increased its full-year revenue guidance.
• The company has reduced its expected cash usage for the full year.

Negatives

• Enterprise customer revenue decreased by 33% in Q3 2024.
• The company reported a net loss of $39.1 million for the third quarter, including a $26 million non-cash expense related to warrants.
• The company expects a net loss of approximately $85 million for the full year.
• Revenue from population sequencing is expected to be zero in Q4 2024 due to the completion of the prior VA MVP task order.

Risks

• The company's future performance is dependent on the timing and pace of new orders from customers.
• The timing of tissue, blood, and other specimen sample receipts from customers can materially impact revenue.
• The company's ability to obtain Medicare coverage and reimbursement for its NeXT Personal Dx test is uncertain.
• The success of the company's clinical sales team and Tempus' sales and marketing efforts is crucial for future growth.
• The company's financial results are subject to fluctuations due to non-cash expenses related to warrant valuations.

Future Outlook

Personalis expects total company revenue in the range of $15 to $16 million for the fourth quarter of 2024, with no revenue from population sequencing. The company has raised its full-year 2024 revenue guidance to $83-$84 million and expects a net loss of approximately $85 million and cash usage in the range of $53 to $55 million.

Management Comments

• Chris Hall, Chief Executive Officer, stated that the 96% biopharma revenue growth attests to increasing customer confidence in the company's technology and platforms.
• Chris Hall also mentioned that the compelling NeXT Personal data provides important clinical evidence to support obtaining Medicare coverage.
• Management expressed confidence in their ability to become a leader in patient testing as they continue to execute on their Win-in-MRD strategy.

Industry Context

The strong growth in biopharma revenue suggests a growing trend in the adoption of personalized medicine and genomic testing in drug development and clinical trials. The company's focus on minimal residual disease (MRD) testing aligns with the industry's increasing emphasis on early cancer detection and monitoring.

Comparison to Industry Standards

• Personalis' 96% year-over-year growth in biopharma revenue is significantly higher than the average growth rate for many companies in the genomics and precision oncology space, suggesting a strong competitive position in this niche.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) are also focused on cancer diagnostics and MRD testing, but Personalis' specific focus on advanced genomics and its partnerships with biopharma companies differentiate it.
• The $143.7 million cash balance provides a solid financial foundation compared to some smaller competitors, allowing for continued investment in research and development and sales expansion.
• The company's ability to raise capital through both private placements with Tempus and the ATM program demonstrates a diversified approach to funding, which is a positive sign compared to companies relying solely on one source of capital.

Related Party Transactions

• The document mentions related party other expense of $26.0 million and $18.3 million for the three and nine months ended September 30, 2024, respectively, as a result of increases since December 31, 2023 in the fair value of the warrants issued to Tempus AI, Inc. (Tempus).
• The document mentions related party current liabilities of $1.7 million as of September 30, 2024.
• The document mentions related party long-term liabilities of $0.6 million as of September 30, 2024.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and increased guidance.
• Employees may feel more secure due to the company's improved financial position.
• Customers, particularly in the biopharma sector, may have increased confidence in Personalis' services.
• The company's ability to secure Medicare coverage will be crucial for future growth and access to a broader patient base.

Next Steps

• Personalis will host a conference call to discuss the third quarter 2024 financial results on November 6, 2024.
• The company will continue to execute on its Win-in-MRD strategy.
• The company will focus on obtaining Medicare coverage for its NeXT Personal Dx test.

Key Dates

Keywords

genomics, precision oncology, biopharma, molecular tests, revenue growth, minimal residual disease, MRD, cancer, Tempus AI, ATM program, Medicare coverage